Harvard Pilgrim and Blue Cross Blue Shield of Massachusetts drop GLP-1 weight-loss coverage

Harvard Pilgrim Health Care and Blue Cross Blue Shield of Massachusetts are both ending coverage of GLP-1 medications for weight loss, with the changes taking hold as employer plans renew beginning January 1, 2026 ^[1][2]. Diabetes prescriptions are unaffected at both insurers.

What changed at each insurer

Harvard Pilgrim's 2026 small-group material for Massachusetts states the carrier "will exclude coverage of all weight loss drugs, including GLP-1 drugs, to treat weight loss and related conditions, such as cardiovascular disease," while GLP-1s remain covered when the prescription is for diabetes ^[1]. The company sells plans in Massachusetts, Maine, Rhode Island and New Hampshire ^[3].

Fully insured groups larger than 100 employees may pay to restore the benefit, MedCity News reported, citing a Harvard Pilgrim spokesperson. In those plans, a member must finish a six-month behavioral modification program before the drug is covered, unless they are already taking it ^[3]. The same spokesperson pointed to a coming wave of FDA approvals for weight-loss drugs aimed at other conditions, saying the step was taken "to ensure affordability of coverage for all our members" ^[3].

Blue Cross Blue Shield of Massachusetts will stop paying for GLP-1s prescribed for weight loss at renewal, a policy that applies to both self-funded and fully insured employers ^[2][3]. Companies above the 100-employee line can keep the benefit if they absorb the added cost; smaller employers and people who buy coverage directly cannot ^[2].

When a plan renews on or after January 1, 2026 without the benefit, existing prior authorizations lapse. Wegovy, Saxenda and Zepbound stop being covered even for members mid-treatment, while Ozempic, Mounjaro, Trulicity and other diabetes GLP-1s stay in place with a documented diabetes diagnosis ^[2]. The insurer describes the change as an exclusion that members cannot appeal, and says premiums will not fall as a result ^[2].

Blue Cross Blue Shield of Michigan also removed weight-loss GLP-1s from coverage ^[3][4]. Effective dates and any employer options there have not been reported.

The price backdrop

List prices for these drugs run from $936 to $1,349 a month before rebates, or roughly $900 to $1,400 a month in one industry analysis ^[3][4]. A Business Group on Health survey found 99% of self-insured employers cover GLP-1s for diabetes and 73% for obesity ^[3].

Patients feel the gap. More than half of GLP-1 users told KFF pollsters that affording the drug is difficult, and more than one in four with insurance said they pay the whole bill themselves ^[4]. Roughly 12% of U.S. adults now report taking one of these medicines, up about six points from early 2024 ^[4].

Insurers are also screening requests more closely. Prior authorization now applies to nearly every GLP-1 prescription, compared with 3% to 5% in 2020 ^[4]. On the ACA marketplaces, only 26 of roughly 300 carriers sell weight-loss GLP-1 coverage, and enrollment holding that benefit shrank from 3.6 million people in 2024 to 2.8 million in 2026 ^[4].

Blue Cross Blue Shield of Massachusetts referred members to manufacturer copay cards and said health savings or flexible spending accounts can be used toward the medication ^[2]. Kelsey Pearse, a spokesperson, said the insurer heard from customers who "are no longer able to bear the burden of paying for these high-priced medications" ^[3].

Why it matters for patients

Access now depends on the employer, not just the insurer, so two people taking the same drug in the same state can get different answers. Blue Cross Blue Shield of Massachusetts said it will notify affected members at least 60 days before renewal ^[2].

Doctors describe limited options for patients who lose coverage. Angela Fitch, an obesity medicine physician and former president of the Obesity Medicine Association, said she directs people to cash-pay channels run by the manufacturers, such as NovoCare or LillyDirect, or shifts them to older drugs that need more follow-up and may bring more side effects ^[3].

How many patients will stop treatment because of these changes has not been reported. Persistence is already low: a Prime Therapeutics study found fewer than a third of people taking GLP-1s for obesity stayed on the drug for a full year, dropping to 15% at two years ^[4].

Medicare does not cover these drugs for weight loss, and North Carolina's Medicaid program is among those pulling back coverage; a proposed rule to expand Medicare and Medicaid access was never finalized ^[3].

What happens next

Employers with more than 100 employees at Blue Cross Blue Shield of Massachusetts will decide on continued coverage in the coming months, and the insurer said members will be contacted no later than 60 days before their renewal date ^[2]. No nationwide tally of people who have lost coverage has been disclosed ^[3].